Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: August 14, 2022

Details for Patent: 7,119,093

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,119,093 protect, and when does it expire?

Patent 7,119,093 protects OFEV and is included in one NDA.

This patent has forty-seven patent family members in thirty-five countries.

Summary for Patent: 7,119,093
Title:3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-an- ilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulpho- nate and the use thereof as a pharmaceutical composition
Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulpho- nate of formula I and the use thereof as a pharmaceutical composition ##STR00001##
Inventor(s): Roth; Gerald J. (Biberach, DE), Linz; Guenter (Mittelbiberach, DE), Sieger; Peter (Mittelbiberach, DE), Rall; Werner (Mittelbiberach, DE), Hilberg; Frank (Wien, AT), Bock; Thomas (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/623,971
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,119,093

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,119,093

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 33 500Jul 24, 2002

International Family Members for US Patent 7,119,093

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 040662 See Plans and Pricing
Argentina 094217 See Plans and Pricing
Austria 551322 See Plans and Pricing
Australia 2003254376 See Plans and Pricing
Brazil 0312811 See Plans and Pricing
Brazil PI0312811 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.